Neurosense Therapeutics Ltd (NRSN) — Tangible Net Worth Ratio
Neurosense Therapeutics Ltd (NRSN) has a Tangible Net Worth Ratio of 100.0% as of December 2024. This metric is calculated by deducting intangible assets ($0.00) from net assets ($2.58 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore NRSN shareholders equity momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Neurosense Therapeutics Ltd Tangible Net Worth Ratio (2019–2024)
This chart shows how Neurosense Therapeutics Ltd's Tangible Net Worth Ratio has changed across 5 annual periods from 2019 to 2024. As of December 2024, the ratio stands at 100.0%, reflecting net assets of $2.58 Million with intangible assets of $0.00 USD. For live market cap and overall valuation, see Neurosense Therapeutics Ltd market cap and net worth.
Annual Tangible Net Worth Ratio for Neurosense Therapeutics Ltd (2019–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Neurosense Therapeutics Ltd from 2019 to 2024, covering 5 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See NRSN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | $2.58 Million | $0.00 | $4.58 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $5.62 Million | $0.00 | $7.71 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $9.01 Million | $0.00 | $11.43 Million | ▲ +0.0 pp |
| 2020 | 100.0% | $659.00K | $0.00 | $779.00K | ▲ +0.0 pp |
| 2019 | 100.0% | $918.00K | $0.00 | $955.00K | — |